Etamicastat
Etamicastat is a peripherally selective dopamine β-hydroxylase inhibitor which was under development for the treatment of hypertension and heart failure but was never marketed. The peripheral selectivity of etamicastat is in contrast to the earlier DBH inhibitor nepicastat, which is centrally active and produced associated side effects. Etamicastat was found to reduce blood pressure but not affect heart rate in clinical trials. The development of etamicastat was discontinued by August 2016.